Cargando…
Derivation and Validation of a Screening Model for Hypertrophic Cardiomyopathy Based on Electrocardiogram Features
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a widely distributed, but clinically heterogeneous genetic heart disease, affects approximately 20 million people worldwide. Nowadays, HCM is treatable with the advancement of medical interventions. However, due to occult clinical presentations and a...
Autores principales: | Guo, Lanyan, Gao, Chao, Yang, Weiping, Ma, Zhiling, Zhou, Mengyao, Liu, Jianzheng, Shao, Hong, Wang, Bo, Hu, Guangyu, Zhao, Hang, Zhang, Ling, Guo, Xiong, Huang, Chong, Cui, Zhe, Song, Dandan, Sun, Fangfang, Liu, Liwen, Zhang, Fuyang, Tao, Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170889/ https://www.ncbi.nlm.nih.gov/pubmed/35686042 http://dx.doi.org/10.3389/fcvm.2022.889523 |
Ejemplares similares
-
Identifying Obstructive Hypertrophic Cardiomyopathy from Nonobstructive Hypertrophic Cardiomyopathy: Development and Validation of a Model Based on Electrocardiogram Features
por: Guo, Lanyan, et al.
Publicado: (2023) -
Novel biomarkers identifying hypertrophic cardiomyopathy and its obstructive variant based on targeted amino acid metabolomics
por: Guo, Lanyan, et al.
Publicado: (2022) -
Characterization of the circulating transcriptome expression profile and identification of novel miRNA biomarkers in hypertrophic cardiomyopathy
por: Guo, Lanyan, et al.
Publicado: (2023) -
Deep learning-derived 12-lead electrocardiogram-based genotype prediction for hypertrophic cardiomyopathy: a pilot study
por: Chen, LaiTe, et al.
Publicado: (2023) -
Excessive branched-chain amino acid accumulation restricts mesenchymal stem cell-based therapy efficacy in myocardial infarction
por: Zhang, Fuyang, et al.
Publicado: (2022)